 <h1>Ayvakit Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>avapritinib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about avapritinib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ayvakit.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to avapritinib: oral tablets</i></p><p>Side effects include:</p><p>Edema, nausea, fatigue, asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation, abdominal pain, constipation, rash, dizziness, decreased hemoglobin concentration, leukopenia, neutropenia, thrombocytopenia, elevated INR, elevated bilirubin concentration, elevated ALT and/or AST concentration, hypophosphatemia, hypokalemia, hypoalbuminemia, hypomagnesemia, elevated S<sub>cr</sub> concentration, hyponatremia. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to avapritinib: oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemoglobin decreased (81%), leukocytes decreased (62%), neutrophils decreased (43%), platelets decreased (27%), international normalized ratio (INR) increased (24%), activated partial thromboplastin time increased (13%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Increased lacrimation (33%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (38%), phosphate decreased (49%), potassium decreased (34%), albumin decreased (31%), magnesium decreased (29%), sodium decreased (28%), weight loss (13%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Cognitive impairment (48%), sleep disorders (e.g., insomnia, somnolence, sleep disorder) (15%), mood disorders (e.g., agitation, anxiety, depression, depressed mood, dysphoria, irritability, mood altered,</p><p>nervousness, personality change, suicidal ideation) (13%)</p><p><b>Common</b> (1% to 10%): Speech disorders, hallucinations<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Bilirubin increased (69%), aspartate aminotransferase increased (51%), alkaline phosphatase increased (14%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (17%), pleural effusion (12%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Edema (e.g., face swelling, conjunctival edema, eye edema, eyelid edema, orbital edema, periorbital edema, face edema, mouth edema, pharyngeal edema, peripheral edema, edema, generalized edema, localized edema, peripheral swelling, testicular edema) (72%), fatigue/asthenia (61%), pyrexia (14%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions (20% or greater) were edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation, abdominal pain, constipation, rash, and dizziness.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (22%), headache (17%), taste effects (e.g., dysgeusia, ageusia) (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (29%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Intracranial hemorrhage (e.g., subdural hematoma, intracranial hemorrhage, cerebral hemorrhage)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., rash, rash maculopapular, rash erythematous, rash macular, rash generalized, rash papular) (23%), hair color changes (21%), alopecia (13%)</p><p><b>Common</b> (1% to 10%): Palmar-plantar erythrodysesthesia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Thyroid disorders (e.g., hyperthyroid, hypothyroid)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (64%), vomiting (38%), diarrhea (37%), abdominal pain (e.g., abdominal pain, upper abdominal pain, abdominal discomfort, lower abdominal pain, abdominal tenderness, epigastric discomfort) (31%), constipation (23%), dyspepsia (16%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ayvakit (avapritinib)." Blueprint Medicines Corporation, Cambridge, MA. </p><h2>More about Ayvakit (avapritinib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: multikinase inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ayvakit &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Gastrointestinal Stromal Tumor</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>